Multispecific antibodies to fight HIV-1 in people
Official title: Multispecific antibodies as therapeutic agents for HIV-1
Funded at Baltimore VA Medical Center · NIH-11189032 · Data updated 2026-11-12
A new approach uses engineered multispecific antibodies to target HIV-1 in people, aiming to improve prevention and treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baltimore VA Medical Center NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | January 1, 2026 |
| Project end | December 30, 2030 |
| Funding year | 2027 |
| NIH project number | 2I01BX004525-05A2 |
| Project ID | NIH-11189032 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with HIV-1 or those at high risk who could benefit from future antibody-based prevention or treatment strategies.
✕Less likely to help
Patients not eligible for future antibody-based therapies or those with contraindications to biologic treatments may not benefit.
What this research studies
This project plans to create novel multispecific antibodies that attack multiple parts of the HIV-1 virus. The work builds on prior antibodies with strong breadth and potency and tests these in humanized mouse models to see if they work better than single antibodies. If successful, the research could lead to therapies that are more effective across diverse HIV strains and help Veterans who live with HIV. The focus is on advancing from promising lab data toward molecules that could be used in people.
Why it matters
Potential benefit: If successful, this could lead to more effective antibody-based therapies for HIV-1 that work across diverse strains and improve patient outcomes.
How similar studies have gone: Previous work with broadly neutralizing antibodies has shown promise, and multispecific designs aim to build on that success.
Where this research is happening
-
Baltimore VA Medical Center
Baltimore, United States Active
Researchers
- Principal investigator: Sajadi, Mohammad Mohseni — Baltimore VA Medical Center
- Study coordinator: Sajadi, Mohammad Mohseni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.